---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-24-071061"
form_type: "8-K"
ticker: "INM"
cik: "0001728328"
company_name: "InMed Pharmaceuticals Inc."
filed_at: "2024-08-20T23:59:59+00:00"
generated_at: "2026-05-31T08:29:08.250832+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# InMed confirms INM-901 oral formulation for Alzheimer's; bioavailability comparable to injection

## Summary
- Preclinical data show oral INM-901 achieves similar brain drug levels as intraperitoneal (IP) injection over 24h.
- Oral delivery offers potential advantages over IV large-molecule antibody therapies, including lower cost and easier access.
- INM-901 is a proprietary small molecule that crosses the blood-brain barrier via GI absorption.
- Company conducting CMC, drug metabolism, dose-ranging, and PK studies to support IND submission.
- Current disease-modifying Alzheimer's treatments require IV infusion every 2-4 weeks at medical facilities.

## SEC filing metadata
- accession: 0001213900-24-071061
- form_type: 8-K
- ticker: INM
- cik: 0001728328
- company_name: InMed Pharmaceuticals Inc.
- filed_at: 2024-08-20T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1728328/000121390024071061/0001213900-24-071061-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1728328/000121390024071061/ea0211922-8k_inmed.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-24-071061
- JSON: https://secwatch.observer/filing/0001213900-24-071061.json
- Plain text: https://secwatch.observer/filing/0001213900-24-071061.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.